Special Issue "Lung Cancer"
A special issue of Cancers (ISSN 2072-6694).
Deadline for manuscript submissions: closed (30 December 2010).
Lung cancer is the leading cause of cancer death in both men and women worldwide. It is becoming apparent, through candidate gene and genome-wide approaches, that clinically evident lung cancers accumulate numerous clonal genetic and epigenetic alterations during a multistep process. These alterations include tumor suppressor gene inactivation and activation of growth or survival promoting oncogenes.
Despite advances in early detection and standard treatment, lung cancer is often diagnosed at an advanced stage and have poor prognoses. The development of innovative, targeted therapies may represent an alternative for the treatment of these cancers.
One of the most important factors that affect survival rate is resistance to therapeutic drugs. Thus development of effective therapeutic approaches is necessary for the management of these common cancers. MiRNAs are attractive drug targets since they regulate expression of many cellular proteins and are differentially
MicroRNAs are small noncoding RNAs that show expression loss or gain in most cancers, and there is growing evidence that they play substantial roles in the pathogenesis and prognosis of human malignancies.
The central focus of the special issue on “Lung Cancer” is identification of molecular pathways involved in lung tumorigenesis and therapeutic resistance. The main topics will include, but are not limited to, the role of cell death (e.g., apoptosis and necrosis) and cell survival pathways (e.g., autophagy) in tumorigenesis and chemotherapy resistance; role microRNAs and their targets in lung prognosis, diagnosis and response to therapy.
Thank you for your collaboration.
Prof. Dr. Gerolama Condorelli
- lung cancer
- cell death
- cell survival
- death receptors
- tumor suppressor genes